<DOC>
	<DOCNO>NCT00159978</DOCNO>
	<brief_summary>Hypoxia tumor cell proliferation important mechanism contribute resistance radiotherapy human head neck tumor cell . Currently , assessment two tumor characteristic perform biopsy use immunohistochemical stain subsequent analysis . A promising non-invasive method characterize tumor use positron-emission tomography ( PET ) . Specific tracer use detect hypoxia proliferative activity . 18F-misonidazole tracer hypoxia 18F-thymidine tracer proliferation . Patients suffer head neck cancer undergo surgery include study . One week surgery patient undergo CT-scan PET-scan either tracer . Shortly surgery give immunohistochemically detectable marker substance enable characterization tumor sample gather resection specimen . These marker pimonidazole detection hypoxia iododeoxyuridine detection tumor cell proliferation . The data collect PET-scan analyse compare result acquire immunohistochemistry .</brief_summary>
	<brief_title>Validation 18F-MISO-PET 18F-FLT-PET</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>Stage IIIV squamous cell carcinoma oral cavity , oropharynx , larynx hypopharynx , plan curative resection . Age &gt; 18 year . Written informed consent . Pregnancy . Prior treatment tumor Women breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>hypoxia</keyword>
	<keyword>tumor cell proliferation</keyword>
	<keyword>PET</keyword>
</DOC>